License Archives | PharmaShots

Roche Signs a Worldwide License Agreement with Parvus Therapeutics to Develop and Commercialize Navacim Platform for Autoimmune Diseases

May 17, 2019May 17, 2019Tuba Khan

Shots: Parvus to receive an upfront & milestones exceeding $800M and royalties on sales of products targeting for IBD, ALD & Celiac diseases, [...]

Exelixis Signs an Exclusive Option and License Agreement with Iconic Therapeutics for Advancing ADC Program

May 17, 2019May 17, 2019Tuba Khan

Shots: Iconic to receive $7.5M upfront, funds for preclinical development and is eligible for option exercise payment, development, regulatory & commercial milestones, royalties [...]

HanX Biopharmaceuticals Signs a License Agreement with Onconova to Develop and Commercialize Rigosertib in Greater China

May 14, 2019May 15, 2019Tuba Khan

Shots: Onconova to receive e $6M upfront including $2M cash, $2M shares & $2M as escrow funding with $45.5M regulatory, development & commercial [...]

AstraZeneca Signs an Exclusive Option and Research Agreement with Transgene for Oncolytic Immunotherapies

May 3, 2019May 6, 2019Tuba Khan

Shots: Transgene to receive $10M upfront & $3M preclinical milestones, providing its oncolytic virus expertise with Vaccinia Virus (TK-, RR-) double-deleted backbone and [...]

Fulcrum Therapeutics Signs an Exclusive Worldwide License Agreement with GSK to Develop and Commercialize Losmapimod for Facioscapulohumeral Muscular Dystrophy

April 24, 2019April 26, 2019Tuba Khan

Shots: GSK to receive shares of Fulcrum’s preferred stock, milestones & royalties on sales of losmapimod. Fulcrum to get exclusive WW rights to [...]

CASI Pharmaceutical Signs an Exclusive Worldwide License Agreement with Black Belt for its TSK011010 Program

April 18, 2019April 24, 2019Shiwani Sharma

Shots: Black Belt to get $5.64M (€5M) upfront, equity investment of $2.26M (€2M), milestones and royalties on sales. CASI to get exclusive WW [...]

BioDelivery Sciences (BDSI) Signs a License Agreement with Shionogi to Commercialize Symproic (naldemedine) in the US

April 11, 2019April 24, 2019Tuba Khan

Shots: Shionogi to receive $30M upfront ($20M as initial payment & additional $10M in 6mos.) and royalties based on the sales of Symproic. [...]

Cognoa Signs an Exclusive License Agreement with Stanford for its Google Glass-based Technology for Children with Autism Spectrum Disorder (ASD)

April 11, 2019April 24, 2019Tuba Khan

Shots: Cognoa to get exclusive license rights for Stanford’s Google Glass-based autism technology to develop & commercialize digital therapies for children with autism [...]

Shanghai Miracogen Signs a Non-Exclusive License Agreement with Synaffix for its ADC Technologies

April 11, 2019April 24, 2019Shiwani Sharma

Shots: Synaffix to receive upfront and milestones leading to total deal value $125M and royalties on sales of product. Miracogen to get non-exclusive [...]

Shanghai Fosun Signs an Exclusive License Agreement with ReNeuron for its CTX and hRPC Cell Therapy in China

April 10, 2019April 24, 2019Shiwani Sharma

Shots: ReNeuron to receive £6.0M ($7.9M) upfront, £6.0M ($7.9M) near-term milestones, £8.0M ($10.5M) regulatory milestones and post-launch profit threshold milestones of 5% on [...]